The fact that EriB has already proved to be effective suppressing tumor growth both in vitro and in vivo highlights that p50 may be a very promising drug target for cancer therapy and EriB can be used as a natural chemical template for the development of p50 targeted therapeutic agents. Here, NFKB1 is linked to cancer.